Lifecore Biomedical (LFCR) said Tuesday it has signed a new 10-year commercial manufacturing and supply agreement with an existing customer.

Financial terms weren't disclosed, and Lifecore didn't identify the customer.

The company said the deal is the latest between the two firms to support the advancement of a new ophthalmic therapy from clinical development to the market.

In conjunction with the agreement, Lifecore said it has also signed a multi-million-dollar statement of work detailing a range of fill-and-finish services that include manufacturing batches of the drug candidate.